)
Visual21 Nov 2025
Data center suppliers
Ascendis Pharma (ASND) investor relations material
Ascendis Pharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Achieved positive operating profit of €11M in Q3 2025, driven by strong YORVIPATH and SKYTROFA sales, marking a shift to sustained revenue and earnings growth.
YORVIPATH revenue reached €143.1M, with expanding patient and prescriber base, especially in the U.S. and commercial launch in Japan.
Continued advancement in growth disorders with U.S. approval of SKYTROFA for adult growth hormone deficiency and progress toward TransCon CNP approval.
Commercial success of YORVIPATH and SKYTROFA has transformed the financial profile, with positive cash flow and operating income.
TransCon CNP under FDA Priority Review with a PDUFA date of November 30, 2025; EMA review ongoing.
Financial highlights
Total Q3 2025 revenue was €214M, up from €57.8M year-over-year, mainly due to YORVIPATH growth.
YORVIPATH global revenue reached €143.1M in Q3, up from €103M in Q2, despite a €3.6M FX headwind.
SKYTROFA contributed €50.7M in Q3, with 3% demand growth offset by a €1.6M FX headwind.
Operating profit for Q3 was €11M, compared to a loss of €96.7M in Q3 2024.
Cash and cash equivalents increased to €539M as of September 30, 2025, from €494M at June 30, 2025.
Outlook and guidance
Expect continued revenue growth in Q4, primarily from YORVIPATH's ongoing global launch and further label expansions for both YORVIPATH and SKYTROFA.
Anticipate presenting 52-week data from the COACH Phase 2 trial of TransCon CNP + TransCon hGH in early 2026.
Plan to initiate Phase 3 trial of TransCon CNP in combination with TransCon hGH and submit IND for hypochondroplasia.
No anticipated major changes in contracting or gross-to-net for YORVIPATH in the near term.
Impact of non-cash finance expense on net loss?
TransCon CNP combination therapy strategy
Detail YORVIPATH's U.S. label expansion plans
What is the YORVIPATH conversion rate trajectory?
How will CNP improve achondroplasia penetration?
Novo Nordisk collaboration status and outlook
Yorvipath payer approval rate trajectory
TransCon CNP: switch vs. de novo patient mix
Novo Nordisk collaboration progress
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ascendis Pharma earnings date
Q4 202511 Feb, 2026
Next Ascendis Pharma earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ascendis Pharma A/S is a biopharmaceutical company leveraging its TransCon technology platform to develop treatments for patients with unmet medical needs in endocrinology and oncology. The company's proprietary TransCon technology is designed to enhance the efficacy, safety, and administration of existing molecules, resulting in new therapies that could potentially offer best-in-class benefits. Ascendis Pharma's approach combines the benefits of prodrug and sustained-release technologies, enabling the controlled release of active pharmaceutical ingredients. The company is headquartered in Copenhagen, Denmark, and its shares are listed on the NASDAQ under the ticker symbol ASND.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage